Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181.

Annals of neurology 2022 Jul

filter terms:

This exploratory case-control study investigates the synaptic marker beta-synuclein in serum and plasma pTau181 in adults with Down syndrome (DS) with (sDS, n = 14) and without (aDS, n = 47) clinical symptoms of Alzheimer disease (AD) as well as euploid controls (n = 23). Beta-synuclein was higher in aDS and more pronounced in sDS (p < 0.0001), whereas pTau181 was only higher in sDS (p < 0.0001). Both markers showed good discriminatory power (area under the curve > 0.90) to distinguish symptomatic from asymptomatic AD. The data indicate that synaptic alterations belong to the earliest AD-associated events in DS and highlight the value of serum beta-synuclein as a potential early marker of AD. ANN NEUROL 2022;92:6-10. © 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Citation

Patrick Oeckl, Olivia Wagemann, Steffen Halbgebauer, Sarah Anderl-Straub, Georg Nuebling, Catharina Prix, Sandra V Loosli, Elisabeth Wlasich, Adrian Danek, Petra Steinacker, Albert C Ludolph, Johannes Levin, Markus Otto. Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181. Annals of neurology. 2022 Jul;92(1):6-10